Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
December $3.5 Million Raise On December 15 th Lexaria issued a press release announcing pricing of a registered direct offering to raise $3.5 million
Instead of targeting a single company or platform, Lilly appears to be challenging the entire compounding model used in the GLP-1 market
However, the total volume in the vial may differ
[3] As of mid-2025, retatrutide has not been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for use in the UK or Europe
US$ 27.04
US$ 28.57
:max_bytes(150000):strip_icc()/not-eating-signs-symptoms-5201896_final-c41f6a10844343059195cfb13e561098.jpg)
US$ 20.68
